CLINICAL TRIALS PROFILE FOR ROXICET
✉ Email this page to a colleague
All Clinical Trials for ROXICET
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00999544 ↗ | Aprepitant Effects on Oxycodone Response | Completed | Merck Sharp & Dohme Corp. | N/A | 2009-10-01 | Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects. |
| NCT00999544 ↗ | Aprepitant Effects on Oxycodone Response | Completed | National Institute on Drug Abuse (NIDA) | N/A | 2009-10-01 | Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects. |
| NCT00999544 ↗ | Aprepitant Effects on Oxycodone Response | Completed | Sharon Walsh | N/A | 2009-10-01 | Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects. |
| NCT00999544 ↗ | Aprepitant Effects on Oxycodone Response | Completed | University of Kentucky | N/A | 2009-10-01 | Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ROXICET
Condition Name
Clinical Trial Locations for ROXICET
Trials by Country
Clinical Trial Progress for ROXICET
Clinical Trial Phase
Clinical Trial Sponsors for ROXICET
Sponsor Name
